tiprankstipranks
Cross Country Healthcare (DE:XXY)
FRANKFURT:XXY
Germany Market
XXY
Cross Country Healthcare
RESEARCH TOOLSreports

Cross Country Healthcare (XXY) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

XXY Analyst Ratings

Hold
6Ratings
Hold
0 Buy
6 Hold
0 Sell
Based on 6 analysts giving stock ratings to
Cross
Country Healthcare
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

XXY Stock 12 Month Forecast

Average Price Target

€11.63
▲(42.65% Upside)
Based on 6 Wall Street analysts offering 12 month price targets for Cross Country Healthcare in the last 3 months. The average price target is €11.63 with a high forecast of €11.63 and a low forecast of €11.63. The average price target represents a 42.65% change from the last price of €8.15.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"€5","12":"€12","6.75":"€6.75","8.5":"€8.5","10.25":"€10.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":11.626213295000001,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€11.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.626213295000001,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€11.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.626213295000001,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€11.63</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,6.75,8.5,10.25,12],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.4,11.417401022692308,11.434802045384616,11.452203068076924,11.46960409076923,11.487005113461539,11.504406136153847,11.521807158846155,11.539208181538463,11.55660920423077,11.574010226923077,11.591411249615385,11.608812272307693,{"y":11.626213295000001,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.4,11.417401022692308,11.434802045384616,11.452203068076924,11.46960409076923,11.487005113461539,11.504406136153847,11.521807158846155,11.539208181538463,11.55660920423077,11.574010226923077,11.591411249615385,11.608812272307693,{"y":11.626213295000001,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.4,11.417401022692308,11.434802045384616,11.452203068076924,11.46960409076923,11.487005113461539,11.504406136153847,11.521807158846155,11.539208181538463,11.55660920423077,11.574010226923077,11.591411249615385,11.608812272307693,{"y":11.626213295000001,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.1,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":11.6,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":11.3,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":11.7,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":10.4,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":8.65,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.9,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.65,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.35,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.9,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.4,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.2,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.4,"date":1782864000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€11.63Average Price Target€11.63Lowest Price Target€11.63
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barrington Analyst forecast on DE:XXY
Kevin Steinke
Barrington
Barrington
€11.63
Hold
42.65%
Upside
Reiterated
06/08/26
Cross Country Healthcare: Hold Rating Maintained Amid Sale to Knox Lane and Limited Near-Term Upside
Truist Financial Analyst forecast on DE:XXY
Tobey Sommer
Truist Financial
Truist Financial
€8.77→€11.63
Hold
42.65%
Upside
Assigned
05/11/26
Analysts Offer Insights on Healthcare Companies: Cross Country Healthcare (NASDAQ: CCRN), Molina Healthcare (NYSE: MOH) and Treace Medical Concepts (NASDAQ: TMCI)
Benchmark Co. Analyst forecast on DE:XXY
Bill Sutherland
Benchmark Co.
Benchmark Co.
―
Hold
―
Downgraded
05/08/26
Cross Country Healthcare downgraded to Hold from Buy at BenchmarkCross Country Healthcare downgraded to Hold from Buy at Benchmark
William Blair Analyst forecast on DE:XXY
Trevor Romeo
William Blair
William Blair
€11.41→
Hold
―
Reiterated
05/08/26
Analysts Offer Insights on Healthcare Companies: Vaxcyte (NASDAQ: PCVX) and Cross Country Healthcare (NASDAQ: CCRN)
Wedbush Analyst forecast on DE:XXY
Michael Piccolo
Wedbush
Wedbush
€11.63
Hold
42.65%
Upside
Reiterated
05/08/26
Cross Country Healthcare downgraded to Neutral from Outperform at WedbushCross Country Healthcare downgraded to Neutral from Outperform at Wedbush
Citizens JMP Analyst forecast on DE:XXY
Constantine Davides
Citizens JMP
Citizens JMP
―
Hold
―
Downgraded
05/07/26
Cross Country Healthcare downgraded to Market Perform from Outperform at CitizensCross Country Healthcare downgraded to Market Perform from Outperform at Citizens
UBS Analyst forecast on DE:XXY
A.J. Rice
UBS
UBS
€7.9→€8.77
Hold
7.66%
Upside
Assigned
03/06/26
Cross Country Healthcare price target raised to $10 from $9 at UBSCross Country Healthcare price target raised to $10 from $9 at UBS
Jefferies Analyst forecast on DE:XXY
Jack Slevin
Jefferies
Jefferies
€7.59
Hold
-6.87%
Downside
Reiterated
12/04/25
Cross Country Healthcare: Hold Rating Amid Acquisition Termination and Uncertain Financial Trajectory
Oppenheimer Analyst forecast on DE:XXY
Michael Wiederhorn
Oppenheimer
Oppenheimer
―
Hold
―
Reiterated
11/19/25
Oppenheimer Reaffirms Their Hold Rating on Cross Country Healthcare (CCRN)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barrington Analyst forecast on DE:XXY
Kevin Steinke
Barrington
Barrington
€11.63
Hold
42.65%
Upside
Reiterated
06/08/26
Cross Country Healthcare: Hold Rating Maintained Amid Sale to Knox Lane and Limited Near-Term Upside
Truist Financial Analyst forecast on DE:XXY
Tobey Sommer
Truist Financial
Truist Financial
€8.77→€11.63
Hold
42.65%
Upside
Assigned
05/11/26
Analysts Offer Insights on Healthcare Companies: Cross Country Healthcare (NASDAQ: CCRN), Molina Healthcare (NYSE: MOH) and Treace Medical Concepts (NASDAQ: TMCI)
Benchmark Co. Analyst forecast on DE:XXY
Bill Sutherland
Benchmark Co.
Benchmark Co.
―
Hold
―
Downgraded
05/08/26
Cross Country Healthcare downgraded to Hold from Buy at BenchmarkCross Country Healthcare downgraded to Hold from Buy at Benchmark
William Blair Analyst forecast on DE:XXY
Trevor Romeo
William Blair
William Blair
€11.41→
Hold
―
Reiterated
05/08/26
Analysts Offer Insights on Healthcare Companies: Vaxcyte (NASDAQ: PCVX) and Cross Country Healthcare (NASDAQ: CCRN)
Wedbush Analyst forecast on DE:XXY
Michael Piccolo
Wedbush
Wedbush
€11.63
Hold
42.65%
Upside
Reiterated
05/08/26
Cross Country Healthcare downgraded to Neutral from Outperform at WedbushCross Country Healthcare downgraded to Neutral from Outperform at Wedbush
Citizens JMP Analyst forecast on DE:XXY
Constantine Davides
Citizens JMP
Citizens JMP
―
Hold
―
Downgraded
05/07/26
Cross Country Healthcare downgraded to Market Perform from Outperform at CitizensCross Country Healthcare downgraded to Market Perform from Outperform at Citizens
UBS Analyst forecast on DE:XXY
A.J. Rice
UBS
UBS
€7.9→€8.77
Hold
7.66%
Upside
Assigned
03/06/26
Cross Country Healthcare price target raised to $10 from $9 at UBSCross Country Healthcare price target raised to $10 from $9 at UBS
Jefferies Analyst forecast on DE:XXY
Jack Slevin
Jefferies
Jefferies
€7.59
Hold
-6.87%
Downside
Reiterated
12/04/25
Cross Country Healthcare: Hold Rating Amid Acquisition Termination and Uncertain Financial Trajectory
Oppenheimer Analyst forecast on DE:XXY
Michael Wiederhorn
Oppenheimer
Oppenheimer
―
Hold
―
Reiterated
11/19/25
Oppenheimer Reaffirms Their Hold Rating on Cross Country Healthcare (CCRN)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BBOTBridgeBio Oncology Therapeutics
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

XXY Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
1
1
1
0
0
Buy
1
2
2
1
0
Hold
6
6
11
7
7
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
8
9
14
8
7
In the current month, XXY has received 0 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. XXY average Analyst price target in the past 3 months is 11.63.
Each month's total comprises the sum of three months' worth of ratings.

XXY Financial Forecast

XXY Earnings Forecast

Next quarter’s earnings estimate for XXY is <€0.01 with a range of -€0.04 to €0.06. The previous quarter’s EPS was -€0.03. XXY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year XXY has Performed in-line its overall industry.
Next quarter’s earnings estimate for XXY is <€0.01 with a range of -€0.04 to €0.06. The previous quarter’s EPS was -€0.03. XXY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year XXY has Performed in-line its overall industry.

XXY Sales Forecast

Next quarter’s sales forecast for XXY is €213.06M with a range of €208.81M to €222.74M. The previous quarter’s sales results were €211.64M. XXY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year XXY has Performed in-line its overall industry.
Next quarter’s sales forecast for XXY is €213.06M with a range of €208.81M to €222.74M. The previous quarter’s sales results were €211.64M. XXY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year XXY has Performed in-line its overall industry.

XXY Stock Forecast FAQ

What is DE:XXY’s average 12-month price target, according to analysts?
Based on analyst ratings, Cross Country Healthcare’s 12-month average price target is 11.63.
    What is DE:XXY’s upside potential, based on the analysts’ average price target?
    Cross Country Healthcare has 42.65% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Cross Country Healthcare a Buy, Sell or Hold?
          Cross Country Healthcare has a consensus rating of Hold, which is based on 0 buy ratings, 6 hold ratings and 0 sell ratings.
            What is Cross Country Healthcare’s share price target?
            The average share price target for Cross Country Healthcare is 11.63. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €11.63 ,and the lowest forecast is €11.63. The average share price target represents 42.65% Increase from the current price of €8.15.
              What do analysts say about Cross Country Healthcare?
              Cross Country Healthcare’s analyst rating consensus is a Hold. This is based on the ratings of 6 Wall Streets Analysts.
                How can I buy shares of Cross Country Healthcare?
                To buy shares of DE:XXY, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.